Identification of a new prognostic score for patients with high-grade metastatic GEP-NEN treated with palliative chemotherapy.

Purpose: High-grade gastroenteropancreatic neuroendocrine neoplasms (GEP-NEN G3) are rare and heterogeneous malignancies with poor prognosis. Aim of this study was to develop prognosticators identifying those patients that derive the most benefit from currently available systemic therapies.

Methods: This retrospective analysis included 78 patients with metastatic GEP-NEN G3.